It has been reported that almost all types of cancers harbor somatic TP53 mutations with varied rates ranging from 50% to 5%.6, 7 Previous studies have suggested that TP53 status is crucial for the response of cancer patients to multiple anticancer therapies. This evidence concerns the gene TP53 and cancer.